abstract |
One is to provide a new and more effective treatment in patients who have failed first-line therapy using SST, or who have failed to respond to somabad monotherapy or somatostatin. . The present disclosure relates to methods of treating or preventing diseases having increased levels of insulin-like growth factor I (IGF-I). The method includes administering to a subject in need a somatostatin analog having agonist activity in combination with an oligonucleotide that targets a growth hormone receptor (GHR). [Selection figure] None |